MicroPort Endovascular MedTech Ltd (688016) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.012x

Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥46.79 Million ≈ $6.85 Million USD) by net assets (CN¥3.98 Billion ≈ $582.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688016 equity to assets ratio to measure how much of total assets are equity-financed.

MicroPort Endovascular MedTech Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how MicroPort Endovascular MedTech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is MicroPort Endovascular MedTech Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.

MicroPort Endovascular MedTech Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Peker Gayrimenkul Yatirim Ortakligi AS
IS:PEKGY
0.126x
Nuvoton Technology Corp
TW:4919
-0.052x
Sanquan Food Co Ltd
SHE:002216
0.057x
PLUXEE NV
PA:PLX
0.434x
Devyani International Limited
NSE:DEVYANI
0.095x
Killam Apartment Real Estate Investment Trust
TO:KMP-UN
0.010x
Fujian Kuncai Material Tech
SHG:603826
0.061x
Mister Car Wash, Inc. Common Stock
NYSE:MCW
0.083x

Annual Cash Flow Conversion Efficiency for MicroPort Endovascular MedTech Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of MicroPort Endovascular MedTech Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is MicroPort Endovascular MedTech Ltd worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥8.62 Billion
≈ $1.26 Billion
CN¥573.06 Million
≈ $83.86 Million
0.066x -32.01%
2024-12-31 CN¥3.82 Billion
≈ $559.35 Million
CN¥373.60 Million
≈ $54.67 Million
0.098x -33.89%
2023-12-31 CN¥3.86 Billion
≈ $565.36 Million
CN¥571.22 Million
≈ $83.59 Million
0.148x -22.81%
2022-12-31 CN¥1.74 Billion
≈ $255.00 Million
CN¥333.76 Million
≈ $48.84 Million
0.192x -2.91%
2021-12-31 CN¥1.52 Billion
≈ $222.73 Million
CN¥300.25 Million
≈ $43.94 Million
0.197x +11.95%
2020-12-31 CN¥1.23 Billion
≈ $180.57 Million
CN¥217.44 Million
≈ $31.82 Million
0.176x +31.17%
2019-12-31 CN¥1.07 Billion
≈ $155.98 Million
CN¥143.20 Million
≈ $20.96 Million
0.134x -72.82%
2018-12-31 CN¥216.16 Million
≈ $31.63 Million
CN¥106.85 Million
≈ $15.64 Million
0.494x +34.01%
2017-12-31 CN¥188.02 Million
≈ $27.51 Million
CN¥69.36 Million
≈ $10.15 Million
0.369x +51.03%
2016-12-31 CN¥123.38 Million
≈ $18.05 Million
CN¥30.13 Million
≈ $4.41 Million
0.244x --

About MicroPort Endovascular MedTech Ltd

SHG:688016 China Medical Devices
Market Cap
$1.65 Billion
CN¥11.29 Billion CNY
Market Cap Rank
#6836 Global
#1421 in China
Share Price
CN¥91.62
Change (1 day)
-1.64%
52-Week Range
CN¥86.08 - CN¥121.45
All Time High
CN¥443.37
About

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more